#United States #Los Angeles, CA #PET imaging #Blue Earth Diagnostics #PSA Levels

Blue Earth Diagnostics to Present at SNMMI 2026

Blue Earth Diagnostics, a subsidiary of Bracco and a leader in the field of positron emission tomography (PET) radiopharmaceuticals, is gearing up to present new findings at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, scheduled from May 30 to June 2 in Los Angeles, California. The company will feature nine research abstracts that highlight the advancements in molecular imaging specifically designed to improve prostate cancer diagnostics.

A key focus will be on novel PET imaging agents that aim to enhance prostate cancer detection rates. Among the highlights is the presentation of data from an intra-patient, head-to-head study comparing the performance of POSLUMA® (flotufolastat F 18) with piflufolastat F 18. This study is particularly noteworthy due to the strong performance of POSLUMA® in detecting biochemical recurrence in patients who have undergone radical prostatectomy, especially at low prostate-specific antigen (PSA) levels—where traditional imaging techniques typically fall short.

The Importance of Accurate Imaging

Prostate cancer, a prevalent form among male patients, often poses challenges in monitoring and treatment planning due to its complex nature. Clinical evidence is crucial for advancing the effectiveness of imaging methods. During the SNMMI meeting, Blue Earth Diagnostics aims to showcase how their solutions are paving the way for improved patient outcomes. Marco Campione, President and CEO, emphasized the role of PET radiopharmaceuticals, stating, "These innovations transform uncertainty into precision for clinicians, offering early insights that lead to clinically meaningful decisions, particularly during critical moments."

In addition to POSLUMA®, data will also be presented related to Axumin® (fluciclovine F 18). Results from a prospective clinical study targeting patients with negative or inconclusive PSMA PET scans further underline the significance of continued innovation in prostate cancer imaging.

Engage with Experts at the Satellite Symposium

Blue Earth Diagnostics encourages attendees of SNMMI 2026 to participate in their upcoming Satellite Symposium titled, "Precision in PSMA: Why Agent Selection Matters More Than Ever," which will occur on Sunday, May 31, from 11:15 AM to 12:15 PM PT at Petree Hall C. This event will provide an excellent opportunity for participants to delve deeper into the implications of these advancements in clinical practice. Furthermore, attendees are invited to visit the Bracco | Blue Earth Diagnostics Exhibit Booth #1823 for more insights and to meet with the team behind these innovative solutions.

Overview of Key Abstracts

A selection of notable abstracts that Blue Earth Diagnostics will present includes:

• - Intra-patient Contemporaneous Comparator Study of the qualitative assessment of urinary radioactivity between 18F-Piflufolastat and 18F-Flotufolastat in patients with biochemical recurrence of prostate cancer.
• - Positive Predictive Value of 18F-Flotufolastat PET in patients undergoing radio-guided salvage surgery for recurrent prostate cancer.
• - Further exploration of imaging heterogeneity in neuroendocrine prostate cancer using paired PSMA and F18-Fluciclovine PET/CT at this year's meeting.

These presentations aim to elucidate the superior capabilities of the latest PET imaging agents in addressing the complex landscape of prostate cancer management, augmenting existing diagnostic frameworks that clinicians rely on.

Conclusion

Bracco, with its nearly century-long commitment to advancing healthcare, continues to be at the forefront of diagnostic imaging breakthroughs. Through Blue Earth Diagnostics, the company is dedicated to enhancing patient care by refining the process of disease detection and improving treatment accuracy. As the SNMMI 2026 meeting approaches, the anticipation is high for the pivotal discussions regarding the latest in molecular imaging for prostate cancer and beyond.

For more details on the session schedules and research presentations, interested parties should consult the SNMMI online program.